Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2022 Earnings Call Transcript

Jason Jones: Yes, sure. So, maybe just a quick update on integration. So, from a systems perspective, ERP and accounting systems, those are fully integrated already. So that integration is complete. On the R&D side, that — we have a plan that includes integrating some systems there that really is going to take through the remainder of the year, this year, it’s kind of incremental. And then, the last area is kind of on pure operations, manufacturing and supply chain. Those are separate functions today and I think that’s a longer process, because the business units are kind of operating as is already. But over the next maybe 12 to 18 months, I think we’ll probably see some more integration on the supply chain and operation side.

Swayampakula Ramakanth: Thank you, both, for taking my question.

Scott Davis: Thank you, RK.

Operator: There are no further questions. Now I’d like to turn the floor back over to Scott Davis for any closing comments.

Scott Davis: All right. Thank you, John, and thanks to everyone for joining us today. 2022 was a transformational year for Ekso Bionics, was highlighted by the successful acquisition of the Indego product line, FDA clearance to market EksoNR for rehabilitation use in patients with MS, and a strong number of EksoHealth bookings. The complementary acquisition of the HMC business was critical to our future growth, principally as it expands our product offering across the continuum of care to home and community use markets. We can now reach more patients in need across the larger market opportunity. We believe that the smooth integration of the HMC business, combined with the continued strong demand for our industry-leading products, has us well positioned to continue our momentum into 2023 and beyond. We look forward to providing updates on our continued progress. Thank you, and have a great day.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation, and have a great day.